FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Transaction

Code (Instr.

8)

5. Number

Derivative

Securities

Acquired

(A) or Disposed

(Instr. 3, 4 and 5)

of (D)

(A) (D) Code ٧ 5)

6. Date Exercisable and Expiration Date

(Month/Day/Year)

Exercisable

Amount

144,185

Expiration

Date

wasnington,	D.C. 2054

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL		
	OMB Number:	3235-0287	
	Estimated average burden		
- 1	hours nor roomanas	. 0.5	

5. Relationship of Reporting Person(s) to Issuer

6. Individual or Joint/Group Filing (Check Applicable

Form filed by One Reporting Person

Form filed by More than One Reporting

6. Ownership Form: Direct

(D) or Indirect

(I) (Instr. 4)

X

10% Owner

below)

Other (specify

7. Nature of

Indirect

See

10. Ownership

Direct (D)

or Indirect (I) (Instr. 4)

Form:

Beneficial

Ownership (Instr. 4)

Footnote(2)

11. Nature of Indirect

Beneficial Ownership

(Instr. 4)

(Check all applicable)

Director

below)

5. Amount of

Securities

Reported

8. Price of Derivative

Security

(Instr. 5)

Beneficially

Owned Following

10,389,579

9. Number of derivative

Securities

Following Reported

(Instr. 4)

Transaction(s)

Owned

Beneficially

Transaction(s)

(Instr. 3 and 4)

Line)

4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and

(A) or (D)

Α

7. Title and Amount of

Securities

Underlying

Security (Instr. 3 and 4)

Amount Number

of Shares

Derivative

Title

Price

\$5.05(1)

Officer (give title

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b) 2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person Aldeyra Therapeutics, Inc. [ ALDX ] PERCEPTIVE ADVISORS LLC 3. Date of Earliest Transaction (Month/Day/Year) (Middle) (Last) (First) 08/01/2022 51 ASTOR PLACE, 10TH FLOOR 4. If Amendment, Date of Original Filed (Month/Day/Year) (Street) **NEW YORK** NY 10003 (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction Date 2A. Deemed 1. Title of Security (Instr. 3) Execution Date, (Month/Day/Year) if any (Month/Day/Year) 08/01/2022 Common Stock Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative 3A. Deemed Execution Date, 3. Transaction Conversion (Month/Day/Year) Security or Exercise if any (Month/Day/Year) Code (Instr. (Instr. 3) Price of Derivative Security Code 1. Name and Address of Reporting Person PERCEPTIVE ADVISORS LLC (Last) (First) (Middle) 51 ASTOR PLACE, 10TH FLOOR (Street) **NEW YORK** 10003 NY (Citv) (State) (Zip) 1. Name and Address of Reporting Person PERCEPTIVE LIFE SCIENCES MASTER **FUND LTD** (Last) (First) (Middle) 51 ASTOR PLACE, 10TH FLOOR (Street) **NEW YORK** NY 10003 (City) (State) (Zip) 1. Name and Address of Reporting Person **EDELMAN JOSEPH** (Last) (First) (Middle)

51 ASTOR PLACE, 10TH FLOOR

(Street)

NEW YORK	NY	10003
(City)	(State)	(Zip)

## **Explanation of Responses:**

1. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$4.97 to \$5.10 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.

2. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

/s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By:

Perceptive Advisors LLC, its 08/03/2022

investment manager, By: Joseph Edelman, its managing

member

/s/ Joseph Edelman - for

Perceptive Advisors LLC, By:

Joseph Edelman, its managing

member

/s/ Joseph Edelman

08/03/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).